Refractory Cutaneous Dermatomyositis With Severe Scalp Pruritus Responsive to Apremilast. (December 2021)

• Record Type: Journal Article
• Authors: Charlton, Devon; Moghadam-Kia, Siamak; Smith, Kristin; Aggarwal, Rohit; English, Joseph C.; Oddis, Chester V.
• Is Part Of: Journal of clinical rheumatology. Volume 27(2021)Supplement 8S
• Publication Date: 2021-12
• Subjects: Rheumatism -- Periodicals; Rheumatology -- Periodicals; Musculoskeletal system -- Diseases -- Periodicals; Musculoskeletal Diseases -- Periodicals; Rheumatic Diseases -- Periodicals; Rhumatisme -- Périodiques; Rhumatologie -- Périodiques; Appareil locomoteur -- Maladies -- Périodiques; Musculoskeletal system -- Diseases; Rheumatism; Rheumatology; Periodicals; 616.723005
• DOI: 10.1097/RHU.0000000000000999
• Languages: English
• ISSNs: 1076-1608

Abstract

Abstract : Abstract: Dermatomyositis (DM) is a subset of idiopathic inflammatory myopathy with characteristic cutaneous manifestations and muscle weakness. Conventional treatments for DM include glucocorticoids and other immunosuppressive or immunomodulatory agents including hydroxychloroquine, methotrexate, azathioprine, mycophenolate mofetil, tacrolimus, cyclosporine, and intravenous immunoglobulin. Refractory patients require more aggressive or novel therapies. Apremilast has not been studied for the management of refractory cutaneous DM. We report a case of a patient with refractory DM with severe scalp pruritus treated with apremilast who demonstrated significant improvement in her skin disease and complete resolution of scalp pruritus.